PMID- 20555330
OWN - NLM
STAT- MEDLINE
DCOM- 20101116
LR  - 20181201
IS  - 1348-4214 (Electronic)
IS  - 0916-9636 (Linking)
VI  - 33
IP  - 8
DP  - 2010 Aug
TI  - Improvement of endothelial function in patients with hypertension and type 2 
      diabetes after treatment with telmisartan.
PG  - 796-801
LID - 10.1038/hr.2010.107 [doi]
AB  - Telmisartan, a selective antagonist for angiotensin type1 receptor and a partial 
      agonist for peroxisome proliferator-activated receptor-gamma, decreases blood 
      pressure and has been shown to improve glucose and lipid metabolism, suggesting 
      potential cardiovascular protective effects. In this study, we investigated 
      whether long-term treatment with telmisartan improved endothelial function in 35 
      hypertensive patients with type 2 diabetes mellitus (T2DM). Office and home early 
      morning blood pressure levels and flow-mediated vasodilation (FMD) were evaluated 
      before and after 12 months of treatment with telmisartan. Blood samples were also 
      obtained for measurement of several biochemical parameters and of adiponectin 
      (AN) and highly sensitive C-reactive protein (hs-CRP) before and after treatment. 
      After 12 months of treatment, office and morning blood pressure levels had 
      significantly decreased, and levels of plasma glucose, glycosylated hemoglobin, 
      total cholesterol, triglyceride and low-density lipoprotein cholesterol had also 
      significantly decreased. Plasma AN and high-density lipoprotein cholesterol 
      levels increased, but hs-CRP levels decreased. Furthermore, FMD significantly 
      increased; changes in percent FMD showed a significant negative correlation with 
      changes in systolic and diastolic blood pressure and a significant positive 
      correlation with changes in AN. Stepwise multivariate regression analysis 
      revealed that changes in plasma AN and office systolic blood pressure were both 
      independent determinants for endothelial function after telmisartan treatment. In 
      conclusion, this study shows that long-term treatment with telmisartan improves 
      not only blood pressure and glucose and lipid metabolism but also endothelial 
      function in hypertensive patients with T2DM, possibly by increased circulating AN 
      and decreased blood pressure.
FAU - Wago, Takehiko
AU  - Wago T
AD  - Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental 
      University Graduate School, Tokyo, Japan.
FAU - Yoshimoto, Takanobu
AU  - Yoshimoto T
FAU - Akaza, Itaru
AU  - Akaza I
FAU - Tsuchiya, Kyoichiro
AU  - Tsuchiya K
FAU - Izumiyama, Hajime
AU  - Izumiyama H
FAU - Doi, Masaru
AU  - Doi M
FAU - Hirata, Yukio
AU  - Hirata Y
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100617
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
RN  - 0 (ADIPOQ protein, human)
RN  - 0 (Adiponectin)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (Blood Glucose)
RN  - 0 (Lipids)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
CIN - Hypertens Res. 2010 Aug;33(8):780-1. PMID: 20555332
MH  - Adiponectin/blood
MH  - Angiotensin II Type 1 Receptor Blockers/*administration & dosage
MH  - Benzimidazoles/*administration & dosage
MH  - Benzoates/*administration & dosage
MH  - Blood Glucose/drug effects
MH  - Blood Pressure/drug effects
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Endothelium, Vascular/*drug effects/physiology
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*drug therapy/metabolism
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Telmisartan
MH  - Treatment Outcome
MH  - Vasodilation/drug effects
EDAT- 2010/06/18 06:00
MHDA- 2010/11/17 06:00
CRDT- 2010/06/18 06:00
PHST- 2010/06/18 06:00 [entrez]
PHST- 2010/06/18 06:00 [pubmed]
PHST- 2010/11/17 06:00 [medline]
AID - hr2010107 [pii]
AID - 10.1038/hr.2010.107 [doi]
PST - ppublish
SO  - Hypertens Res. 2010 Aug;33(8):796-801. doi: 10.1038/hr.2010.107. Epub 2010 Jun 
      17.